Neuren`s NNZ-2591 shows benefit in rare neurodevelopmental disorder
28 May 2024 //
PR NEWSWIRE
Neuren Phase 2 trial shows significant improvements in Pitt Hopkins syndrome
27 May 2024 //
BIOSPACE
The Neuren Pharmaceuticals (ASX:NEU) share price has soared 102%
21 Dec 2021 //
FOOL
Neuren submits IND application for NNZ-2591 in Phelan-McDermid syndrome
21 Sep 2021 //
THEMARKETHERALD
ACADIA announce Rare Pediatric Disease Designation for Trofinetide
09 Mar 2020 //
BIOSPECTRUM ASIA
ACADIA & Neuren Announce Rare Pediatric Disease Designation for Trofinetide
04 Mar 2020 //
BUSINESSWIRE